Stockscreener 앱 받기
95.06
1.08%
1.02
시장 영업 전:
94.45
-0.61
-0.64%
전일 마감가:
$94.04
열려 있는:
$93.5
하루 거래량:
3.10M
Relative Volume:
1.18
시가총액:
$20.76B
수익:
$819.56M
순이익/손실:
$-1.18B
주가수익비율:
-16.55
EPS:
-5.7434
순현금흐름:
$-951.64M
1주 성능:
-1.26%
1개월 성능:
-19.67%
6개월 성능:
-33.91%
1년 성능:
-40.63%
1일 변동 폭
$0.00
$0.00
1주일 범위
$93.33
$97.88
52주 변동 폭
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
95.06 | 20.76B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-09-24 | 재개 | Goldman | Buy |
| 2026-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2026-03-30 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-12-19 | 재개 | Truist | Buy |
| 2025-12-04 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 개시 | Jefferies | Buy |
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
The Escalator: CSL, Insmed, Amgen and more - Medical Marketing and Media
Insmed names former Sanofi and Novartis CEO Hudson and biopharma exec Koppikar to board - ROI-NJ
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Zacks Investment Research
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Form 4 Insmed Inc: Paul Hudson (Director) For: 19 October By Investing.com - Investing.com Canada
Utpal Koppikar Appointed to Insmed Board, Reports No Ownership of Company Securities - Kalkine Media
Insmed Appoints Two New Directors to Its Board - Insmed Incorporated Investor Relations
Insmed adds two directors with pharma leadership experience - Investing.com
Insmed appoints Paul Hudson and Utpal Koppikar to its Board - TradingView
Insmed adds two independent directors with biopharma backgrounds - StreetInsider
Oral Lung-Disease Tablets: Insmed Brings BRINSUPRI to Japan for NCFB - Trend Hunter
Insmed launches bronchiectasis treatment in Japan By Investing.com - Investing.com Canada
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan - Yahoo Finance
Insmed IncorporatedLaunches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases - TradingView
Insmed launches four phase 3 trials for lung disease therapy By Investing.com - Investing.com Canada
Three trials have started for Insmed's inhaled treatment; a fourth is expected in the first half of 2027. - Stock Titan
Insmed Incorporated (INSM) Options Chain - Yahoo! Finance Canada
Three presentations will examine an inhaled treatment being studied for high blood pressure in the lungs. - Stock Titan
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $169 to $220 - Moomoo
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM) - The Globe and Mail
Insmed Shares Fall After Wolfe Research Downgrade - Yahoo Finance
Wolfe Research Downgrades Insmed to Peer Perform From Outperform - Moomoo
Truist previews biotech earnings with focus on Insmed, BridgeBio By Investing.com - Investing.com Canada
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
BofA cuts Insmed stock price target on valuation concerns By Investing.com - Investing.com India
Weekly Recap: ARIKAYCE sNDA Jan 28, 2027 FDA date and CFO Bonstein exit - TradingView
Wolfe Research Downgrades Insmed to Peer Perform From Outperform - Yahoo Finance
US High Growth Tech Stocks Spotlight Featuring 3 Top Picks - Simply Wall Street
UBS reiterates Insmed stock rating on Brinsupri sales outlook - Investing.com
Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative? - Yahoo Finance
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - Zacks Investment Research
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - TradingView
Bonstein to step down as Insmed chief financial officer - ROI-NJ
$100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today - Benzinga
Insmed Announces CFO Transition - Insmed Incorporated Investor Relations
Insmed stock falls as CFO Sara Bonstein to step down - Investing.com
Why is Insmed stock sliding today? By Investing.com - Investing.com India
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed - Benzinga
Insmed stock falls as CFO Sara Bonstein to step down - Yahoo Finance
Insmed drops as investors weigh CFO departure despite reaffirmed 2026 outlook - Quiver Quantitative
Insmed Incorporated Announces Sara Bonstein Steps Down as Chief Financial Officer, Effective October 30, 2026 - marketscreener.com
Insmed Incorporated Reaffirms Earnings Guidance for the Full-Year 2026 - marketscreener.com
Insmed Q2 2026 Earnings Call Transcript - Benzinga
Insmed CFO Sara Bonstein to step down, reaffirms guidance - TradingView
Insmed CFO Sara Bonstein to step down on October 30 By Investing.com - Investing.com Canada
Insmed CFO Sara Bonstein to step down Oct 30; c... - pluang.com
Insmed CFO Sara Bonstein to Separate, Search Underway for Successor - TradingView
Insmed (INSM) Announces CFO Transition - TradingView
Insmed Announces CFO Transition - Yahoo Finance
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Insmed Inc 주식 (INSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Brennan David R | Director |
Sep 09 '26 |
Proposed Sale |
123.99 |
25,000 |
3,099,729 |
0 |
| SHAROKY MELVIN MD | Director |
Aug 17 '26 |
Sale |
127.53 |
5,000 |
637,650 |
0 |
| MELVIN SHAROKY | Director |
Aug 17 '26 |
Proposed Sale |
127.53 |
5,000 |
637,637 |
0 |
| Roger Adsett | Officer |
Aug 10 '26 |
Proposed Sale |
133.26 |
239,850 |
31,963,198 |
0 |
| Adsett Roger | Chief Operating Officer |
Aug 10 '26 |
Option Exercise |
20.45 |
239,850 |
4,905,570 |
338,594 |
| Adsett Roger | Chief Operating Officer |
Aug 10 '26 |
Sale |
133.27 |
239,850 |
31,964,810 |
98,744 |
| Martina Flammer | Officer |
Aug 06 '26 |
Proposed Sale |
128.61 |
27,173 |
3,494,755 |
0 |
| Flammer Martina M.D. | Chief Medical Officer |
Aug 06 '26 |
Option Exercise |
21.20 |
27,173 |
576,126 |
87,659 |
| Flammer Martina M.D. | Chief Medical Officer |
Aug 06 '26 |
Sale |
128.61 |
27,173 |
3,494,838 |
60,486 |
| Lewis William | Chair and CEO |
Jul 23 '26 |
Sale |
106.06 |
10,700 |
1,134,890 |
259,058 |
1.77%
3.08%
자본화:
|
볼륨(24시간):